Last reviewed · How we verify
Placebo for ABT-333
Placebo for ABT-333 is a Small molecule drug developed by AbbVie (prior sponsor, Abbott). It is currently in Phase 3 development.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
At a glance
| Generic name | Placebo for ABT-333 |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish baseline efficacy and safety of an investigational drug by comparison. In Phase 3 trials for ABT-333, the placebo arm allows researchers to distinguish true drug effects from natural disease progression and placebo response. Any observed benefits in the placebo group reflect non-pharmacological factors such as patient expectation and natural recovery.
Approved indications
Common side effects
Key clinical trials
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PHASE3)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE2)
- Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects (PHASE1)
- ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for ABT-333 CI brief — competitive landscape report
- Placebo for ABT-333 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI
Frequently asked questions about Placebo for ABT-333
What is Placebo for ABT-333?
How does Placebo for ABT-333 work?
Who makes Placebo for ABT-333?
What development phase is Placebo for ABT-333 in?
Related
- Manufacturer: AbbVie (prior sponsor, Abbott) — full pipeline
- Compare: Placebo for ABT-333 vs similar drugs
- Pricing: Placebo for ABT-333 cost, discount & access